Utilizing AI and cutting-edge technology, the IvyGene Platform acts as a highly accurate biomarker to confirm multiple cancers early. Unlike many biomarkers, the IvyGene tests combine high sensitivity and specificity through a simple blood draw.
AI and Next-Generation Sequencing identified gene targets that have higher methylation levels when cancer is present. Circulating tumor DNA (ctDNA) is more highly methylated than other cell-free DNA (cfDNA) at those specific gene targets. By analyzing the methylation ratios at those specific gene targets in whole blood, the IvyGene Technology may confirm the presence of multiple cancers, as early as stage 1.

Westbury, NY

Family Medicine, New York, New York

Integrative Oncologist, Alpharetta, GA
“Saving lives and changing the status quo of cancer detection”
Learn more about confirming the presence of cancer today.
Laboratory for Advanced Medicine
1201 Cumberland Avenue, Suite B West Lafayette, IN 47906